Bio X Cell, LLC, a producer of monoclonal antibodies for preclinical in vivo research, has appointed Christopher Conway as Chief Executive Officer.
 
Mr. Conway most recently served as President of R&D at Curia and brings extensive experience in both small molecule and biologics drug discovery. Chris joined Curia (formerly AMRI) in 2008 from Johnson & Johnson and held a series of commercial leadership roles. In 2015 he was promoted to Senior Vice President and Drug Discovery and Development Business Unit Head leading a period of significant growth culminating in his promotion to President of the R&D business unit in 2019 and P&L leadership of twenty sites globally.
 
“As my successor, Chris not only brings strong business and industry credentials, but an understanding and respect for Bio X Cell’s culture and mission to advance scientific discovery and innovation by providing the highest quality products and exceptional customer service,” said the Company’s founder, Klaus Lubbe. Dr. Lubbe sold a majority stake in BXC to Windjammer Capital Investors (“Windjammer”) in November 2023 and remains involved, particularly with respect to new product development, as a board member and minority shareholder.
 
“Bio X Cell’s tremendous brand reputation throughout the global research community, especially within academia and government, is a testament to the care and attention Klaus and team have brought to the business since its founding in 1997,” said Mr. Conway. “The opportunity to build on that strong foundation, continue to expand upon Bio X Cell’s high quality, extensive product offering, and extend its reach within the commercial sector, both organically and through strategic acquisitions, are what attracted me to the CEO role.”